Just launched · October 2026—Rankings get sharper with every edition.Spotted an error?Tell us →
Sign in / Register

VarmX

ActiveOn the Netherlands Radar · not ranked

Haemostasis · Netherlands

Biotech developing a modified clotting factor to reverse severe bleeding in patients treated with factor Xa inhibitor anticoagulants.

Last roundFunding round · Mar 2025

Why VarmX is not ranked yet

How the Radar works →

The Radar lists every known eligible company, sorted by date of last round, with no AI judgement. VarmX enters the ranking once its public data is sufficient for the AI to estimate it. Next Netherlands edition: 8 Nov 2026.

Funding history

DateRoundAmountTypeInvestors
Mar 2025Funding roundUSD 16M—EIC Fund

Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.

Uback rankings

How the AI ranks →
RankingTierRankEditionNext update
Netherlands · all sectorsRadar—Edition 0 · October 20268 Nov 2026

Independent analyses

By industry professionals & analysts

Industry professionals and financial analysts can publish their own analysis of VarmX as a PDF. It must answer at least one of these four questions, and stick to them:

ValuationWhat is VarmX worth?
Versus competitorsHow does it compare?
Who should acquire itStrategic buyers, and why
Who should it acquireAcquisition targets, and why
Publish an analysisName, role and LinkedIn shown · public sources only

Analyses are the opinion of their authors, not of Uback. They are checked before publication.

Comparable companies in Netherlands

Full Netherlands ranking →

Last updated: Oct 2026Report an error

Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.